Objective: The objective of this study was to investigate the molecular mechanisms involved in rapamycin-induced inhibition of tumor growth.
Materials And Methods: Murine S180 sarcoma cells were subcutaneously injected into mice, and the tumor-bearing mice were randomly divided into three groups (vehicle control, 2 mg/kg rapamycin, and 4 mg/kg rapamycin). The effect of rapamycin on tumor growth was determined by measuring tumor volume. Mammalian target of rapamycin (mTOR), Beclin1, ULK1, LC3, Notch1, CD133, and CD90 expressions was confirmed using confocal microscopy and Western blotting.
Results: The tumor growth inhibition rates induced by high-dose and low-dose rapamycin were 48.8% and 30.1%, respectively. Beclin1 and ULK1 expressions and the LC3-II/LC3-I ratio in tumor tissues were altered by rapamycin, whereas mTOR, Notch1, CD133, and CD90 expressions were significantly inhibited by rapamycin in immunofluorescence assays. Western blotting also showed similar results.
Conclusion: Tumor growth delay induced by rapamycin may be associated with the suppression of the cancer stem cell phenotype (Notch1, CD133, and CD90) and promotion of autophagy (mTOR, Beclin1, ULK1, and LC3-II/LC3-I ratio) in the murine S180 sarcoma model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/jcrt.JCRT_639_18 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buthionine sulfoximine acts synergistically with doxorubicin as a sensitizer molecule on different tumor cell lines.
J Toxicol Environ Health A
January 2025
Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Federal University of Piauí, Teresina-PI, Brazil.
The chemotherapeutic drug doxorubicin (DOX) has been widely used for treating solid tumors attributed to its antiproliferative effectiveness; however, its clinical use is limited due to side effects, including cardiotoxicity, myelosuppression, and drug resistance. Combining DOX with buthionine sulfoximine (BSO), a glutathione (GSH) synthesis inhibitor, showed promising results in overcoming these adverse effects, potentially reducing the required DOX dose while maintaining efficacy. The aim of the present study was to examine the effects of different concentrations of BSO and DOX, both individually and in combination, utilizing B16/F10 (murine melanoma), SNB-19 (human glioblastoma), S180 (murine sarcoma), and SVEC4-10 (murine endothelial) cell lines.
View Article and Find Full Text PDFCurcumin-Modified Selenium Nanoparticles Improve S180 Tumour Therapy in Mice by Regulating the Gut Microbiota and Chemotherapy.
Int J Nanomedicine
December 2024
School of Life Science and Medicine, Shandong University of Technology, Zibo, 255000, People's Republic of China.
Purpose: This study aimed to synthesize curcumin-modified selenium (Cur/Se) nanoparticles via a simple and green method for tumour treatment and explore their effects on the gut microbiota.
Methods: Curcumin was applied as a reducing and capping agent for the construction of Cur/Se nanoparticles with Tween 80 as a stabilizer. The drug release behaviour and DPPH and ABTS radical scavenging activities of the Cur/Se nanoparticles were detected.
The double face of licorice-kansui herb pair: Cure or curse, depending on the combining ratio and mediated by hydrogen sulfide.
Phytomedicine
January 2025
State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), Co-construction Collaborative Innovation Center for Chinese Medicine Resources Industrialization by Shaanxi & Education Ministry, Shaanxi Innovative Drug Research Center, Shaanxi University of Chinese Medicine, Xianyang 712046, China. Electronic address:
Background: The safety and efficacy of herbal medicines including traditional Chinese medicine (TCM) has been one of the major scientific problems in the medical field. In TCM prescriptions, reasonable herbal combinations bring stronger efficacy and low risk of toxicity. However, the rules and mechanisms for herbal combinations are far from complete understood yet.
View Article and Find Full Text PDFTailoring Plasmonic Nanoheaters Size for Enhanced Theranostic Agent Performance.
Bioengineering (Basel)
September 2024
Laboratory of Biomedical Optics and Imaging, Federal University of Pernambuco, Recife 50740-540, Brazil.
The introduction of optimized nanoheaters, which function as theranostic agents integrating both diagnostic and therapeutic processes, holds significant promise in the medical field. Therefore, developing strategies for selecting and utilizing optimized plasmonic nanoheaters is crucial for the effective use of nanostructured biomedical agents. This work elucidates the use of the Joule number (Jo) as a figure of merit to identify high-performance plasmonic theranostic agents.
View Article and Find Full Text PDFComparison of the accumulation manner of a macromolecular drug between two mouse tumour models: study with magnetic resonance imaging and the model macromolecular drug, gadolinium-conjugated dextran.
J Drug Target
February 2025
Laboratory of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
Article Synopsis
- * Gd-Dex shows preferential accumulation in the marginal regions of S180 tumors shortly after injection, while the distribution in RIF-1 tumors is more uniform.
- * The research highlights that the differences in drug distribution and pharmacokinetics between tumor types can influence the effectiveness of targeted nanomedicine delivery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!